Morgan Stanely Assumes Coverage on Edwards Lifesciences (EW) with an Equalweight
More News related to EW
- The Edwards Lifesciences Fund Awards More Than $1.8 Million to 81 Nonprofit Organizations
- Edwards Lifesciences and DexCom to Develop Continuous Glucose Monitoring Products for Hospital Market
- Edwards Lifesciences to Present at the 2008 Credit Suisse Healthcare Conference
- Edwards Lifesciences Mourns Passing of Board Member Philip M. Neal
- Edwards Lifesciences (EW) Reports Mixed Q3 Earnings; Guides Q4, Raises FY08 EPS Outlook
More News related to New Coverage
- Post Properties (PPS) Announces Reduction In Quarterly Dividend To 20c, CIO Departure and New Stock Buyback Of Up To $200M
- Roberts Realty Investors (RPI) Increases Stock Repurchase Program
- United American Healthcare (UAHC) Approves $1 Million Stock Buyback
- Quidel Corporation (QDEL) Extends Current Stock Buyback Plan
- Quidel (QDEL) Adds $25M to Buyback Program
Morgan Stanely assumes coverage on Edwards Lifesciences (NYSE: EW) with an Equalweight.
Edwards Lifesciences Corporation (Edwards Lifesciences) is a global player in products and technologies designed to treat cardiovascular disease.
Related Categories
New CoverageStocks Mentioned
+0.14Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
